Cerner real-world data (CRWD) - A de-identified multicenter electronic health records database.

(CRWD) is a de-identified big data source of multicenter electronic health records. Cerner Corporation secured appropriate data use agreements and permissions from more than 100 health systems in the United States contributing to the database as of March 2022. A subset of the database was extracted to include data from only patients with SARS-CoV-2 infections and is referred to as the Cerner COVID-19 Dataset.

Systemic quinolones and risk of retinal detachment III: a nested case-control study using a US electronic health records database.

Background: Quinolones are popular antibiotics that are known for their potency, broad coverage, and reasonable safety. Concerns have been raised about a possible association between quinolones and retinal detachment (RD).

Methods: We conducted a nested case-control study using electronic health records (EHR) from the Health Facts® Database.

Association of treatments for acute appendicitis with pregnancy outcomes in the United States from 2000 to 2016: Results from a multi-level analysis.

Background: Open appendectomy, laparoscopic appendectomy, and non-surgical treatment are three options to treat acute appendicitis during pregnancy. Previous studies on the association of different treatment methods for acute appendicitis with pregnancy outcomes have been limited by small sample sizes and residual confounding, especially with respect to hospital-level factors. This study aimed to investigate the association of treatment method for acute appendicitis with pregnancy outcomes using a multi-level analysis.

Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.

Background And Aim: Quinolones are globally popular antibiotics with proven potency, broad coverage, and reasonable safety. However, some concerns were raised as to their possible association with acute liver failure (ALF). The aim of this study is to assess ALF risk within 30 days of receiving a systemically administered quinolone antibiotic, in individuals with no history of liver/diseases.